Fax: (011) 41 22 379 49 71
Version of Record online: 24 JAN 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 6, pages 1288–1295, 15 March 2011
How to Cite
Bouchardy, C., Benhamou, S., Schaffar, R., Verkooijen, H. M., Fioretta, G., Schubert, H., Vinh-Hung, V., Soria, J.-C., Vlastos, G. and Rapiti, E. (2011), Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer, 117: 1288–1295. doi: 10.1002/cncr.25638
This study was an oral presentation at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009 in San Antonio, Texas.
CB, SB, and ER contributed to the study design, oversaw the project, and drafted the final manuscript. HS was responsible for data collection. RS and GF were responsible for statistical analyses. HMV, JCS, VVH, and GV advised on the analysis and participated in data interpretation. All authors critically reviewed the manuscript
- Issue online: 4 MAR 2011
- Version of Record online: 24 JAN 2011
- Manuscript Accepted: 30 JUN 2010
- Manuscript Revised: 21 JUN 2010
- Manuscript Received: 13 APR 2010
- lung cancer;
- breast cancer;
- mortality risk;
- population-based study
The Women's Health Initiative randomized clinical trial reported that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of anti-estrogens should be associated with decreased lung cancer mortality risk. The authors compared lung cancer incidence and mortality among breast cancer patients with and without anti-estrogen therapy.
Our study included all 6655 women diagnosed with breast cancer between 1980 and 2003 and registered at the Geneva Cancer Registry. Among these women, 46% (3066) received anti-estrogens. All women were followed for occurrence and death from lung cancer until December 2007. The authors compared incidence and mortality rates among patients with and without anti-estrogens with those expected in the general population by Standardized Incidence Ratios (SIRs) and Standardized Mortality Ratios (SMRs).
After a total of 57,257 person-years, 40 women developed lung cancer. SIRs for lung cancer were not significantly decreased among breast cancer patients with and without anti-estrogens (0.63, 95% confidence intervals [CI], 0.33-1.10; and 1.12, 95% CI, 0.74-1.62, respectively) while SMR was decreased among women with anti-estrogens (0.13, 95% CI, 0.02-0.47, P<.001) but not for women without anti-estrogens (0.76, 95% CI, 0.43-1.23).
Compared with expected outcomes in the general population, breast cancer patients receiving anti-estrogen treatment for breast cancer had lower lung cancer mortality. This study further supports the hypothesis that estrogen therapy modifies lung cancer prognosis. Cancer 2011. © 2011 American Cancer Society.